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Prion protein (PrP) is a required factor for susceptibility to transmissible spongiform encephalopathy or
prion diseases. In transgenic mice, expression of prion protein (PrP) from another species often confers
susceptibility to prion disease from that donor species. For example, expression of deer or elk PrP in transgenic
mice has induced susceptibility to chronic wasting disease (CWD), the prion disease of cervids. In the current
experiments, transgenic mice expressing two naturally occurring allelic variants of deer PrP with either glycine
(G) or serine (S) at residue 96 were found to differ in susceptibility to CWD infection. G96 mice were highly
susceptible to infection, and disease appeared starting as early as 160 days postinfection. In contrast, S96 mice
showed no evidence of disease or generation of disease-associated protease-resistant PrP (PrPres) over a
600-day period. At the time of clinical disease, G96 mice showed typical vacuolar pathology and deposition of
PrPres in many brain regions, and in some individuals, extensive neuronal loss and apoptosis were noted in
the hippocampus and cerebellum. Extraneural accumulation of PrPres was also noted in spleen and intestinal
tissue of clinically ill G96 mice. These results demonstrate the importance of deer PrP polymorphisms in
susceptibility to CWD infection. Furthermore, this deer PrP transgenic model is the first to demonstrate
extraneural accumulation of PrPres in spleen and intestinal tissue and thus may prove useful in studies of
CWD pathogenesis and transmission by oral or other natural routes of infection.
Prion diseases, also known as transmissible spongiform en-
cephalopathies (TSE diseases), are progressive brain diseases
characterized by spongiform neurodegeneration of the central
nervous system. These diseases include scrapie in sheep, bo-
vine spongiform encephalopathy (BSE) in cattle, chronic wast-
ing disease (CWD) in deer and elk of North America, and
Creutzfeldt-Jakob disease (CJD) in humans. In all prion dis-
eases, the pathogenic process is associated with the presence
of an abnormally folded partially protease-resistant protein,
PrPres, derived from the normal isoform of protease-sensitive
host-encoded prion protein, PrPsen. PrPres is likely to be an
important trigger of the neurodegenerative process. Many in
the field believe that ingestion or inoculation of PrPres itself
can transmit the disease, but this remains controversial (1, 9,
31). Although TSE agents show species specificity, in certain
situations, the infectious agents can cross into new species and
can eventually adapt to new species by continued passage (32).
Sheep scrapie has been recognized for at least 200 years, and
horizontal spread is known to occur from mothers to offspring
as well as via contaminated pastures. Other forms of prion
disease were not recognized until the 1900s. The origin of all
these diseases is unclear. There has been much speculation
that the diseases in humans, cattle, and cervids might have
originated from an adapted form of sheep scrapie; however,
this hypothesis has not been proven (38). CWD was first de-
scribed in captive mule deer in Colorado in 1964 and has since
been detected in both captive and wild deer and elk herds in a
widening area of the United States and Canada (38). CWD
spreads horizontally, and infection appears to be enhanced by
crowding, which occurs in farmed herds (27). In some areas,
CWD spread in wild deer has also been extensive. In wild elk,
CWD infection can also occur, but the extent of horizontal
spread is uncertain at present. There is also concern over the
possibility that CWD might be able to spread to humans or
domestic animals exposed to cervids or cervid tissues. There-
fore, it is of importance to understand the host genetic factors
that might influence CWD spread among cervids and other
species.
Normal mice are resistant to CWD from deer or elk, but
recently, several publications have described successful CWD
infection in transgenic (Tg) mice expressing PrPsen of deer or
elk (7, 21, 22, 35). Therefore, cervid PrP appears to be an
important species-specific factor in susceptibility to deer or elk
prion disease. Furthermore, in deer populations, different PrP
molecules with glycine or serine at position 96 (30) and serine
or phenylalanine at position 225 (18) have been described.
Some of these PrP sequence variations might modify resistance
or susceptibility to CWD in deer because variations at several
positions in sheep PrP are known to influence resistance to
* Corresponding author. Mailing address: Rocky Mountain Labora-
tories, 903 South Fourth St., Hamilton, MT 59840. Phone: (406) 363-
9354. Fax: (406) 363-9289. E-mail: bchesebro@nih.gov.
 Published ahead of print on 21 February 2007.
4533
 at LAN
D
BO
UW
UNIVERSITEIT on Novem
ber 20, 2008 
jvi.asm.org
D
ow
nloaded from
 
scrapie (3, 5, 14). However, all four of the previous studies of
cervid PrP Tg mice used deer or elk PrP alleles with glycine at
position 96. In the current study, in order to test whether the
allelic variation at this position in deer PrP might be important
for susceptibility, we generated deer PrP Tg mice with either
glycine (G) or serine (S) at position 96. Following intracerebral
infection, mice expressing G96 deer PrP were susceptible to
four deer or elk CWD pools. In contrast, mice expressing S96
deer PrP were resistant to these same pools. These results
suggest that allelic variation in deer PrP may be an important
factor in resistance to CWD infection in vivo.
MATERIALS AND METHODS
Generation of deer PrP transgenic mice. Transgenic mice expressing deer PrP
were generated using standard procedures. Plasmid DNA encoding the half
genomic mouse PrP (pHGPrP) (12) was modified to encode deer PrP with either
the G96 or S96 allele. A 5-kb portion of unsequenced DNA was removed from
the promoter region of pHGPrP by digestion with BamHI followed by religation.
Unique SalI and XhoI sites were removed by digestion with SalI and XhoI
followed by religation. Most of the mouse PrP open reading frame (ORF) was
removed by digestion with AgeI and SfoI, and this region was replaced by an
oligonucleotide polylinker containing AgeI, NsiI, BstEII, MluI, XhoI, and SfoI
restriction enzyme sites as described previously (10). The remaining mouse PrP
ORF downstream from the signal peptide was removed by digestion with PshAI
(in the mouse PrP signal peptide sequence) and XhoI (in the polylinker). The 5
portion of the deer PrP ORF was inserted in this position between PshAI and
XhoI by ligation of two upper strand and two lower strand oligonucleotides as
follows: 5ATGTCGGCCTCTGCAAGAAGCGACCAAAACCTGGAGGAG
GATGGAACACCG3 (upper1), 5GTGGGAGCCGATACCCGGGACGCGT
GCATGCCTCGAG3 (upper2), 5TCGAGGCATGCACGCGTCCCGGGTA
TCGGCTCCCACCGGTGTTCCAT 3 (lower1), and 5CCTCCTCCAGGTTT
TGGTCGCTTCTTGCAGAGGCCGACAT3 (lower2).
After reannealing, these oligonucleotides encoded deer PrP from the PshAI
site in the mouse PrP signal peptide to the SmaI site in deer PrP and also
contained MluI, SphI,and XhoI sites at the 3 end. To replace the unsequenced
mouse PrP DNA removed in the first step above, the plasmid was digested with
NotI and BspEI, and a 6.2-kb NotI-to-BspEI fragment from pHGPrP was in-
serted. To introduce the remainder of the 3 deer PrP ORF, a 0.67-kb SmaI-to-
SalI fragment encoding the 3 two-thirds of deer PrP G96 or S96 excised from the
respective pTZnot clones (33) was inserted from SmaI to XhoI. The GenBank
accession number for the G96 clone was AF156185, and the accession number
for the S96 clone was AF156184. To remove the bacterial plasmid DNA, the final
plasmids, p65-7 (G96 allele) and p97-7 (S96 allele), were digested with NotI and
SbfI, and the large eukaryotic DNA fragment was purified and used to generate
transgenic mice using PrP null mice (25). The transgene was maintained with the
mouse PrP null genotype by selective crossing and PCR analysis as described
previously (10). The PrP produced from this transgene has the mouse PrP signal
peptide followed by the deer PrP ORF, but after cleavage of the signal peptide,
the mature PrP is identical to the PrP from deer.
CWD pools. Four CWD pools used in these studies were from the following
groups. The Deer 1 group consisted of captive white-tailed deer, deer 94W05803(WY),
95W10089(WY), 97W6570(CO), 97W6571(CO), 97W07231(CO), 98W00770(WY),
and 98W06348(CO) (Elizabeth Williams, Department of Veterinary Sciences, Univer-
sity of Wyoming, Laramie, WY). The Deer 2 group consisted of free-ranging mule deer,
deer 02W643, 01W10027, 00W8741, 00W13445, 01W11102, and 00W11673 (E. Wil-
liams). The Deer 3 group consisted of captive Colorado mule deer, deer 03-407541,
03-465081, 03-464506, and 03-460516 (Michael Miller, Colorado Division of Wildlife,
Wildlife Research Center, Ft. Collins, CO). The Elk group consisted of free-
ranging elk, elk 98W12019 and 01W12716 (E. Williams). In elk and mule deer,
the G96 PrP is the only type detected (6, 33). In contrast, white-tailed deer
express S96 PrP and/or G96 PrP (19, 30). Thus, the brains of the white-tailed
deer in the Deer 1 pool used in this study might contain either one or both
alleles. Unfortunately, it was not possible to genotype the animals used in this
pool.
Immunoblotting. Brain samples were prepared for analysis of PrPsen as pre-
viously described (10). Samples were frozen at 20°C until electrophoresed on
a 16% acrylamide gel (Invitrogen) in 25 mM Tris, 250 mM glycine, and 0.1%
sodium dodecyl sulfate (SDS). Each lane contained 2.7 mg brain equivalents.
Immunoblots were probed first with anti-PrP monoclonal antibody L42 (R-
Biopharm) (36) at 0.2 g/ml. This antibody recognizes PrP sequences from
residues 145 to 163 in sheep (23) and cross-reacts strongly with deer and elk PrP.
Blots were next probed with horseradish peroxidase-conjugated sheep anti-
mouse immunoglobulin G at 0.25 g/ml (Amersham). After the development of
enhanced chemiluminescence according to the manufacturer’s recommendations
(Amersham), blots were exposed to film for visualization of protein bands.
To demonstrate PrPres, tissues were made into a 20% (wt/vol) homogenate in
0.01 M Tris HCl (pH 7.4) and 0.005 M MgCl and then sonicated in a cup-horn
sonicator for 1 min. Twenty microliters of the 20% homogenate was adjusted to
100 mM Tris HCl (pH 8.3), 1% Triton X-100, and 1% sodium deoxycholate in
31 l. Samples were treated with 50 g/ml concentration of proteinase K (PK)
for 1/2 h at 37°C. The reaction was stopped by adding 2 l of 0.1 M phenyl-
methylsulfonyl fluoride and placed on ice for 5 min. An equal volume of 2
sample buffer was added, then tubes were boiled 5 min and run on SDS-
polyacrylamide gels, and blots were probed with anti-PrP monoclonal L42. For
detection of extraneural PrPres, the ultracentrifugation method was used to
concentrate the PrPres (10), and 20 mg equivalents of original tissue were added
to each lane. For N-glycosidase F (PNGase F) treatment (New England Biolabs)
of PrPsen and PrPres samples, reaction conditions were as recommended by the
manufacturer except denaturing of 4 mg brain equivalents was done in SDS-
polyacrylamide gel electrophoresis sample buffer. Each sample was digested
using 2,500 U of PNGase F and incubated overnight at 37°C. Samples were
frozen at 20°C until analyzed by immunoblotting.
Histopathology. Tissues were removed, fixed in neutral buffered formalin, and
embedded in paraffin (20). PrPres was detected by immunostaining with mono-
clonal anti-PrP antibody F99/97.6.1 (28) plus biotinylated rabbit anti-mouse
F(ab)2 (Jackson Labs) followed by horseradish peroxidase-conjugated streptavi-
din using an autoclaving protocol (20). Hematoxylin and eosin staining was done
using routine methods. Terminal deoxynucleotidyltransferase-mediated dUTP-
biotin nick end labeling (TUNEL) staining (green) with 4,6-diamidino-2-phe-
nylindole (DAPI) nuclear staining (blue) was done using the Roche in situ cell
death detection kit. Formalin-fixed deparaffinized sections were permeabilized
with Neuropore (Trevigen) for 20 min and rinsed three times with phosphate-
buffered saline prior to exposure to kit reagents for 1 h at 25°C. After the sections
were rinsed, they were mounted in Prolong Gold Anti-Fade reagent with DAPI
(Invitrogen) and examined in a fluorescence microscope.
Animal studies. Each 4- to 6-week-old mouse received 50 l of a 1% brain
homogenate of one of the four CWD pools described above. This inoculum was
administered by injection through the skull into the parietal region of the brain
using a 27-gauge needle. Mice were observed daily for signs of clinical disease.
The earliest signs were usually mild gait abnormalities. This progressed to severe
wobbling gait, tremors, ataxia, and weakness with a leg clasping reflex. Subse-
quently, there was a state of marked inactivity with maintenance of a hunched
posture in spite of stimuli. This latter status was defined as severe clinical disease
FIG. 1. (A) Immunoblot detection of brain expression of PrPsen in
transgenic mouse lines expressing deer PrP. Each lane was loaded with
2.7 mg equivalents of brain homogenate. (B) Immunoblot comparison
of PrPsen levels in brains of mule deer, white-tailed deer, and line 33
and line 39 Tg heterozygous mice expressing deer PrP. In panel B,
dilutions were 1:1, 1:2, and 1:4. Lanes with 1:1 dilutions had 0.8 mg
equivalent of brain. Two or three mice from each line were tested in
two or more replicate experiments with three different monoclonal
antibodies (L42, D18, and F99/97.6.1). The results were consistent in
all these tests, so only the L42 data were presented.
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and was recorded as the end point in the data presented. Typically, mice in this
condition were sacrificed, as they would progress to a moribund status within 2
or 3 days. In these assays, the duration of clinical signs from onset to end stage
was from 30 to 50 days, which was longer than usually observed with standard
mouse scrapie strains, such as 22L and RML. Prion disease was confirmed by
analysis of brain tissue for PrPres by immunoblotting.
RESULTS AND DISCUSSION
Analysis of PrPsen expression. Transgenic founder mice
were identified by DNA hybridization and PCR. Deer PrP
expression was analyzed by reverse transcription-PCR using
mRNA from adult brain tissue of Tg/ mice. By this assay,
high expression was found in G96 Tg lines 15, 33, and 39 as
well as in S96 Tg lines 60 and 80 (data not shown). By Western
blot analysis, brain deer PrPsen protein expression was highest
in line 33, was about 30% lower in line 60, and was about 50%
lower in lines 15, 39, and 80 (Fig. 1A). Brain PrPsen level in
line 33 was slightly higher than the levels seen in brains of
uninfected mule deer and white-tailed deer, and the levels in
line 39 were similar to the levels in both types of deer (Fig. 1B).
CWD infection of deer PrP transgenic mice. Mice from all
five Tg lines were inoculated with four different sources of
CWD infectivity. Brain tissue was analyzed for the presence of
PrPres by Western blotting to confirm the clinical diagnosis
of CWD. PrPres showed partial protease resistance associated
with the approximate 6- to 9-kDa reduction in molecular size
typically seen in CWD and other prion diseases (Fig. 2). This
size difference was more accurately visualized when samples
were also digested with PNGase F to remove carbohydrates
(Fig. 2, compare lanes 2 and 4).
In these experiments, all three Tg lines expressing the G96
deer PrP molecules appeared susceptible to clinical CWD in-
duced by all four CWD pools tested. Line 33 mice developed
severe disease from 200 to 400 days postinfection (dpi), and
the differences among the mice with CWD induced by the four
CWD pools were minimal (Fig. 3). Line 15 mice which ex-
pressed about 50% less deer PrP in brain developed severe
disease from 160 to 450 dpi. Line 39 mice also developed
severe clinical CWD with detectable brain PrPres at times
similar to those of lines 33 and 15, but many of these mice
succumbed to dermatitis prior to the onset of CWD signs (data
not shown). In contrast to the G96 deer PrP mice, lines 60 and
80, which expressed S96 deer PrP, showed no signs of clinical
CWD after inoculation of any of the four pools up to 600 dpi
(Fig. 3). Furthermore, random sacrifice of 33 infected mice
between 276 and 600 dpi showed no mice with PrPres in brain
detectable by immunoblotting. In addition, five mice sacrificed
at 600 dpi showed no PrPres in the spleen or gut by immuno-
blotting. The lack of disease and PrPres in S96 deer PrP Tg
mice did not appear to be due to low PrP expression levels
because the levels in both line 60 and 80 were similar to or
higher than the levels in line 39 (G96) and line 15 (G96) mice
(Fig. 1). Therefore, G96 deer PrPsen appeared to facilitate
susceptibility of transgenic mice to CWD infection by these
four pools, whereas S96 deer PrPsen did not.
Brain PrPres glycoform patterns. In some cases, strain vari-
ation in prion diseases has been correlated with different
PrPres banding patterns on immunoblot analysis (8, 11). To
look for CWD strains in our model, immunoblots of brain
PrPres from line 33 mice infected with the four different CWD
pools were compared. These blots did not show any differences
FIG. 4. Comparison of PrPres from line 33 Tg mice expressing deer
PrP infected with four different CWD pools. Pairs of mice infected
with each pool were sacrificed at the time of clinical disease from 301
to 371 dpi. None of the Tg mice appeared to have different PrPres
banding patterns. Elk brain from a wild elk with clinical CWD was
used for comparison, and its pattern differed only slightly from that of
the CWD-infected Tg mice.
FIG. 2. Comparison of PrPsen and PrPres in Tg mice expressing
deer PrP (line 33). The brain from an uninfected Tg mouse expressing
deer PrP was used for analysis of PrPsen. Brain homogenate from a Tg
mouse infected 301 days earlier with Deer 1 CWD pool was treated
with proteinase K () to detect PrPres. Both samples were analyzed
with () and without () digestion with PNGase F to remove carbo-
hydrates.
FIG. 3. Survival curves for transgenic mice expressing deer PrP
inoculated intracerebrally with four different CWD brain pools. Line
33 G96 Tg mice were inoculated with Deer 1 CWD pool (n  12) (E),
Deer 2 CWD pool (n  20) (), Deer 3 (n  13) CWD pool (‚), and
elk CWD pool (n 14) (ƒ). For line 15 G96 Tg mice (n 19) () and
lines 60 and 80 of S96 Tg mice (n  26) (■), pooled data from mice
inoculated with all four CWD pools are shown. The graph shows time
from inoculation to severe clinical neurological disease. Brain tissue
was tested by immunoblotting for PrPres to confirm the diagnosis of
CWD. Age-matched line 33 Tg mice, which were inoculated with
healthy brain homogenate or sham inoculated, showed no signs of
clinical disease, and brain PrPres was not detected by immunoblotting.
The time of earliest detectable clinical disease, usually mild gait ab-
normality, was 30 to 50 days earlier than the time to severe clinical
disease which was reported in this figure. Curves were compared by the
Kruskal-Wallis test, and no significant differences among the G96 (line
33 and line 15) mice were found.
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FIG. 5. PrPres detection and pathology in brain tissue of line 33 Tg mice expressing deer PrP at various times after CWD infection. (A) Dense
PrPres accumulations in the brain stem detected by monoclonal antibody F99/97.6.1 at 371dpi; (B) PrPres ”florid” plaque surrounded by vacuoles
(arrows) in anterior cerebral cortex at 371 dpi, detected as described above for panel A. (C to H) hematoxylin-and-eosin-stained sections; (C) large
vacuoles in anterior cerebral cortex at 337 dpi; (D) normal cerebellar granule cell layer in uninfected mouse; (E) abnormal cerebellar granule cell
layer at 413 dpi; (F) vacuoles and neuronal damage in dentate gyrus of hippocampus at 337 dpi; (G) normal cerebellar granule layer neurons
(arrows) in uninfected mouse; (H) loss of cerebellar granule layer neurons (arrows) at 371 dpi. (I) Staining of PrPres (arrows) with monoclonal
antibody F99/97.6.1 in a spleen follicle of deer PrP Tg mouse 288 days after infection with Deer 1 CWD pool. (J) Apoptotic bodies and small
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in PrPres banding patterns among mice infected with the dif-
ferent pools (Fig. 4). Thus, by this test, there was no evidence
for the presence of different CWD strains in the elk and deer
pools tested. Control mice inoculated with normal brain ho-
mogenate and sham-inoculated mice had no detectable PrPres.
Brain tissues from Tg mice inoculated with CWD pools or
with normal brain homogenate or sham-inoculated mice
were examined histologically for sites of PrPres deposition and
pathology. Control mice showed no evidence of PrPres. CWD-
inoculated mice had plaque-like PrPres accumulation and vac-
uolar pathology in numerous areas of the central nervous sys-
tem (Fig. 5A and B and Table 1). G96 deer PrP Tg mice
inoculated with each of the four CWD pools showed similar
regional distribution of pathology and PrPres deposition. Al-
though the PrPres deposits were often in dense disc-like accu-
mulations resembling amyloid plaques, staining with Thioflavin
S or Congo red was negative, suggesting that this material was
not a classical amyloid in nature. This result differed from that
reported by others using different lines of cervid PrP Tg mice
(7, 35).
Brain histopathology and PrPres distribution. In different
brain regions, there appeared to be evidence for two types of
histological damage: vacuolation of the gray matter and neu-
ronal apoptosis. These two processes were not always coinci-
dent. The cerebellar granular layer had massive neuronal loss
(Fig. 5E and H) compared to this layer in age-matched control
mice (Fig. 5G). Apoptotic bodies were often seen together
with positive TUNEL staining (Fig. 5J and K), but in the
cerebellum, this process was associated with only moderate
vacuolation and PrPres deposition (Table 1). In one transgenic
elk PrP model, infection with elk CWD was also reported to
induce marked apoptosis and neuronal loss in the cerebellar
granule cell layer (21). In contrast to our results in the cere-
bellum, the hippocampus had very prominent vacuolation (Fig.
5F), as well as evidence for apoptosis and neuronal loss (not
shown). The deeper forebrain regions also had striking vacu-
olation (Fig. 5C) which was often associated with dense round
20- to 30-micron PrPres deposits (florid plaques) (Fig. 5B), but
neuronal loss was not obvious, and only minimal TUNEL
staining was observed (not shown). Both of these types of
pathology were seen in mice infected with all four CWD pools
studied. However, neuronal loss and apoptosis were less prom-
inent in animals that had a more rapid clinical onset and were
sacrificed at earlier time points, suggesting that apoptosis was
not the primary process leading to clinical disease in this
model.
Detection of PrPres outside brain. In many prion diseases,
including CWD, PrPres can be detected in extraneural sites,
such as tonsil, spleen, and lymph nodes. Therefore, we exam-
ined several tissues for evidence of PrPres in the G96 deer PrP
Tg mice intracerebrally infected with CWD. By immunoblot-
ting using monoclonal antibody L42, significant PrPres signals
were found in brain, eye, spleen and intestinal tissue, but kid-
ney, tongue, heart, and skeletal muscle were all negative (Fig.
6). Liver, testes, and lung were also negative (not shown). By
immunohistochemistry, PrPres in spleen was consistent with
possible location in follicular dendritic cells and macrophages
associated with follicles (Fig. 5I). PrPres in intestine appeared
to be located primarily in neuronal ganglia between the mus-
cular layers (Fig. 5L), but PrPres was also noted in mesenteric
lymph nodes and Peyer’s patches in some mice (not shown).
Using sensitive biological infectivity assays, the CWD infec-
tious agent was recently found in saliva and blood (26) and
skeletal muscle (2) of CWD-infected deer. However, by immu-
noblotting, which is less sensitive, we failed to detect PrPres in
pyknotic nuclei (arrows) in cerebellar granule cell layer at 289 dpi. (K) TUNEL-positive nuclei (yellow arrows) in cerebellar granular cell layer at
289 dpi. TUNEL-positive cells were not seen in uninfected mice. (L) Punctate PrPres staining in neuronal ganglion cells in lower gut of deer PrP
Tg mouse 288 days after infection with Deer 1 CWD pool. Bars, 200 microns (A, G, and H), 50 microns (B, J, K, and L), 20 microns (C to F),
and 10 microns (I).
FIG. 6. Immunoblot analysis of PrPres in various tissues of CWD-
infected line 33 Tg mice expressing deer PrP. PrPres was concentrated
by the ultracentrifuge method as described in Materials and Methods,
and 20 mg equivalents of tissue were added to each lane. Results are
representative of data from five mice infected with each of the four
CWD pools tested.
TABLE 1. Regional distribution of PrPres, vacuolar pathology, and
neuronal loss in the brains of transgenic mice expressing deer
PrP with G96 inoculated with four CWD pools
Brain region
Regional distributiona of:
PrPres Vacuoles Neuronalloss
Olfactory bulb   
Forebrain   
Cerebral cortex   
Corpus callosum   
Hippocampus   
Thalamus   
Habenula   
Hypothalamus   
Superior colliculus   
Cerebellum   
Brain stem   
a Using three or four mice inoculated with each CWD pool, PrPres, vacuoles,
and neuronal loss in various regions were graded on a relative scale from 
(little) to  (abundant or striking). Examples are shown in Fig. 5: 
vacuoles in forebrain and hippocampus in Fig. 5C and F;  vacuoles in
cerebellum in Fig. 5E;  neuronal loss in cerebellum in Fig. 5E and
H;  PrPres in forebrain in Fig. 5B. No apparent differences in regional
pathology were noted among the four CWD pools.
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skeletal muscle of CWD-infected Tg mice (Fig. 6). We also
failed to detect PrPres in heart tissue of these mice, similar to
results with CWD-infected mule deer heart but differing from
results with elk heart and white-tailed deer heart (17). There-
fore, there are likely to be species differences among cervids
and Tg mice which account for these discrepancies.
None of the four previous studies of cervid PrP transgenic
mice reported on studies of extraneural PrPres. One paper
stated that no PrPsen was found in non-brain tissues and as-
cribed this finding to the use of a modified promoter (7). The
finding of PrPres in spleen and intestinal tissue in our line 33
Tg mice indicated that there was sufficient extraneural PrPsen
in these tissues to allow PrPres generation. Thus, these mice
should prove very useful in studies of peripheral CWD patho-
genesis by oral or other possible natural routes of infection.
The most striking discovery from the present studies was the
finding that two deer PrP alleles differed in the ability to confer
sensitivity to CWD. Previous transgenic mouse studies have
analyzed only G96 deer or elk PrP alleles, which were found to
confer susceptibility to deer and elk CWD in all studies so far.
In contrast, this is the first study testing the S96 deer PrP allele
in transgenic mice, and it was surprising to find that this allele
failed to confer susceptibility to any of the four CWD pools
tested. Of course, it is possible that these mice will develop
disease or PrPres at a later time point past the present 600-day
observation period.
Our results are similar but not identical to results of natu-
rally occurring CWD in white-tailed deer where S96 homozy-
gous deer appear to be partially resistant to CWD. Neverthe-
less, at least three such deer have been documented to develop
CWD as diagnosed by immunohistochemical PrPres detection
in the brain stem (obex) (19, 30).
It is presently unclear exactly how the allelic variation at PrP
residue 96 might influence prion disease susceptibility. At a
molecular level, deer and elk PrP residue 96 is located in the
flexible disordered tail of the N-terminal domain near the
globular domain (15). In transgenic mice, expression of PrP
constructs with various deletions indicated that the region
around residue 96 was important for scrapie susceptibility (13,
34, 37). In addition, molecular PrP conversion studies using
N-terminus-deleted PrP showed that the region between resi-
dues 94 and 106 influenced the type and amount of PrP con-
version (24). However, in other cell-free conversion studies,
G96 and S96 deer PrP were found to convert equally well when
incubated with CWD from several cervid sources (33). There-
fore, in CWD-infected deer, the influence of differing amino
acid residues at position 96 probably does not act by alteration
of the PrP conversion process.
An alternative explanation of the resistance of S96 PrP Tg
mice to CWD infection is that deer expressing G96 or S96 PrP
might be preferentially infected by different CWD strains. This
selectivity for different strains or isolates has been found in
sheep scrapie. Sheep carrying the so-called PrP VRQ allele are
more susceptible to VRQ-derived isolates, like SSBP/1, but are
more resistant to non-VRQ-derived isolates, like CH1641. In
contrast, PrP ARQ carriers or breeds usually resist SSBP/1 but
are highly susceptible to CH1641 (14, 16). This selectivity has
been further supported by the underlying molecular conver-
sion process in which VRQ and ARQ prion proteins are more
rapidly converted by their homologous VRQ or ARQ PrPres
molecules (4).
Although no distinct CWD strains have been identified so
far, a recent study of CWD infection in cervid PrP Tg mice
described a mule deer CWD pool which differed from other
pools by its inability to induce vacuolation in the anterior
cerebral cortex and olfactory bulb (22). Such regional pathol-
ogy differences might be due to the existence of a variant CWD
strain.
In our experiments, the CWD pools, Deer 2, Deer 3, and
Elk, are likely to have come from G96 animals because both
mule deer and elk appear to be homozygous for G96 PrP (6,
29). In uninfected white-tailed deer, the S96/S96 homozygous
genotype exists naturally at a low frequency (5 to 9%), but its
incidence is even lower (0.3 to 3%) in CWD-infected animals
(19, 30). Therefore, homozygous S96 PrP deer may not be
represented in our Deer 1 pool of CWD-infected white-tailed
deer. In future experiments, CWD agent derived from ho-
mozygous S96 PrP white-tailed deer will have to be tested in
our S96 deer PrP Tg mice to search for a unique CWD strain.
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